In Vitro Toxicology

MuriGenics performs a variety of in vitro toxicity screens and assays. Performing in vitro cytotoxicity assays prior to animal testing may be a cheaper alternative for initial drug screens. Since many of these tests require cell-based assays, our experience in cell biology, enables us to analyze cells using molecular and biochemical techniques as well as morphologically.

In Vitro Myelotoxicity

Myelotoxicity is a serious side-effect of many chemotherapeutic and immune-suppressive agents. This condition can lead to serious life-threatening infection and neutropenic sepsis. MuriGenics provides a panel of screens designed to help our clients gain insight into the likelihood and degree to which their compounds may produce myelotoxicity and thus aid them in lead candidate selection. Below is our panel of screens:

  • CFU-GM (Colony Forming Unit Granulocyte Monocyte) for Neutropenia
  • CFU-GEMM (Colony Forming Unit Granulocyte Erythrocyte, Monocyte Megakaryocyte) for Multipotential Cytopenias
  • BFU-e (Busrt Forming Unit Erythroid for Erythropenia)
  • CFU-Mk (Colony Forming Unit Megakaryocyte) for Thrombocytopenia
  • Cytometry
  • Hematopoietic Assays
  • Long Term Cultures (LTCIC) Assays
  • Characterization of Hematopoietic Cells

In Vitro Hepatotoxicity – Rat

Drug-induced hepatic injury is a common reason for the withdrawal of an approved drug. Drug-induced hepatotoxicity ranges from asymptomatic elevation of liver enzymes to fulminant hepatic failure. We perform a series of assay screens that may be utilized throughout the discovery and development phases in conjunction with traditional in vivo methods to aid the client in the selection of a lead compound. Below is a list of assessments that we perform:

  • Morphological Evaluation
  • LDH Leakage
  • MTS
  • Pathology Specific Hepatotoxicity
    • Steatosis
    • Phospholipidosis
  • CYP Inhibition/Induction (Drug/Drug Interactions)
    • bDNA – Luminex xMAP Platform
    • ATPase Assay (Transporters)